Flash Covid-19 drug statement from the World Health Organization

Flash Covid-19 drug statement from the World Health Organization

The World Health Organization (WHO) announced that they recommend the orally taken Covid-19 drug developed by the Pfizer pharmaceutical company for those who do not have severe Covid-19 disease but have a high risk of being hospitalized.

In the article published in the British Medical Journal of the International Experts Guideline Development Group affiliated with the organization, the antiviral active substance that experts have been researching for a while “nirmatrelvir” and “ritonavir”Data on the effectiveness of Pfizer’s Covid-19 drug, made from a combination of

According to AA’s report Experts tried the drug on 3,100 Covid-19 patients to examine its effectiveness.

In this context, it has been reported that WHO recommends Pfizer’s antiviral drug for people who have mild Covid-19 disease but have a high rate of hospitalization.

It was noted that those at high risk of being hospitalized included those who did not receive vaccination, advanced age and those with suppressed immunity.

It was concluded that the risk of hospitalization is prevented in Covid-19 patients included in these groups using the said Covid-19 drug, and the drug made from ritonavir is more effective than other types of antiviral drugs.

The World Health Organization last recommended the use of rheumatoid arthritis drugs Baricitinib and Interleukin-6 in the treatment of Covid-19 on January 14.

Related News

similar posts

Leave a Reply